Recent discovery and development of inhibitors targeting coronaviruses
Related Experiment Video
Updated: Dec 29, 2025

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Thanigaimalai Pillaiyar1, Sangeetha Meenakshisundaram2, Manoj Manickam3
1PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Abstract:
Human coronaviruses (CoVs) are enveloped viruses with a positive-sense single-stranded RNA genome. Currently, six human CoVs have been reported including human coronavirus 229E (HCoV-229E), OC43 (HCoV-OC43), NL63 (HCoV-NL63), HKU1 (HCoV-HKU1), severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), and MiddleEast respiratory syndrome (MERS) coronavirus (MERS-CoV). They cause moderate to severe respiratory and intestinal infections in humans. In this review, we focus on recent advances in the research and development of small-molecule anti-human coronavirus therapies targeting different stages of the CoV life cycle.
Related Concept Videos
Enzyme Inhibition
Drug Discovery: Overview

